# Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

> **NCT03087071** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 59 (actual)

## Conditions studied

- EGFR NP_005219.2:p.S492R
- KRAS Gene Mutation
- MAP2K1 Gene Mutation
- Metastatic Colorectal Adenocarcinoma
- Refractory Colorectal Adenocarcinoma
- Stage IV Colorectal Cancer AJCC v7
- Stage IVA Colorectal Cancer AJCC v7
- Stage IVB Colorectal Cancer AJCC v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Panitumumab
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT03087071
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-29
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03087071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03087071, "Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03087071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*